Truegotfredsen3014

Z Iurium Wiki

Verze z 30. 12. 2024, 23:40, kterou vytvořil Truegotfredsen3014 (diskuse | příspěvky) (Založena nová stránka s textem „Purpose The aim of this study is to evaluate the survival rate and prognostic factors of anaplastic gliomas according to the 2016 World Health Organization…“)
(rozdíl) ← Starší verze | zobrazit aktuální verzi (rozdíl) | Novější verze → (rozdíl)

Purpose The aim of this study is to evaluate the survival rate and prognostic factors of anaplastic gliomas according to the 2016 World Health Organization classification, including extent of resection (EOR) as measured by contrast-enhanced T1-weighted magnetic resonance imaging (MRI) and the T2-weighted MRI. Materials and Methods The records of 113 patients with anaplastic glioma who were newly diagnosed at our institute between 2000 and 2013 were retrospectively reviewed. There were 62 cases (54.9%) of anaplastic astrocytoma isocitrate dehydrogenase (IDH) wild-type (AAw), 18 cases (16.0%) of anaplastic astrocytoma, IDH-mutant, and 33 cases (29.2%) of anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted. Xevinapant concentration Results The median overall survival (OS) was 48.4 months in the whole anaplastic glioma group and 21.5 months in AAw group. In multivariate analysis, age, preoperative Karnofsky Performance Scale score, O6-methylguanine-DNA methyltransferase (MGMT) methylation status, postoperative tumor volume, and EOR measured from the T2 MRI sequence were significant prognostic factors. The EOR cut-off point for OS measured in contrast-enhanced T1-weighted MRI and T2-weighted MRI were 99.96% and 85.64%, respectively. Conclusions We found that complete resection of the contrast-enhanced portion (99.96%) and more than 85.64% resection of the non-enhanced portion of the tumor have prognostic impacts on patient survival from anaplastic glioma.in English, Hungarian A 2019. év végén, elsőként a kínai Vuhan városában megjelenő, SARS-CoV-2 béta-koronavírus okozta járványt 2020. március 11-én világjárvánnyá minősítette az Egészségügyi Világszervezet. Magyarországon 2020. március 4-én jelentették az első megerősített COVID–19-esetet, s március 15-én vesztette életét az első, új típusú koronavírussal fertőzött beteg. Az elhunyt halálának pillanatában nem állt rendelkezésre központi, egységes irányelv, mely tisztázta volna a szükséges óvintézkedések körét, illetve egyértelmű leírást nyújtott volna a tetem biztonságos kezeléséhez. A halottak patológiai osztályra való szállítása, tárolása, esetleges boncolása, majd végső nyughelyre helyezése, ezek mikéntje számtalan kérdést vet fel. A fertőző betegségekre, illetve a halottakkal kapcsolatos teendőkre vonatkozó hatályos jogszabályok nem tartalmaznak elégséges információt egy COVID–19-fertőzött beteg halála utáni feladatok végrehajtását illetően. Az országos tisztifőorvos március 19-én felfüggesztette a boncolzámára kivitelezhető, az ellátók biztonságát növelő javaslatokat, ajánlásokat fogalmazunk meg.* Orv Hetil. 2020; 161(17) 713–722.Background Inhaler errors among patients with chronic obstructive pulmonary disease (COPD) can reduce treatment efficacy. Methods This randomized, open-label, crossover study evaluated correct use of ELLIPTA versus DISKUS plus HandiHaler. Participants with COPD attended at least 3 study visits (Day 1 [Visit 1], Day 28 [Visit 2], and Day 56 [Visit 3]). Inhalers contained placebo; usual maintenance medication was continued. Participants were randomized to an inhaler sequence (ELLIPTA then DISKUS plus HandiHaler, or the reverse) and preference questionnaire at Visit 1. Participants read the instructions for use in the approved prescribing information for their inhaler(s) and correct use was assessed at Visit 1 (verbal guidance provided if required). Correct use was reassessed at Visit 2, and with the next inhaler(s) at Visit 3. Primary endpoint was the proportion of participants demonstrating correct use (0 errors) with the assigned inhaler(s) after 28 days. Results A greater proportion of study participants (n = 217) correctly used ELLIPTA (96%) versus DISKUS plus HandiHaler (87%) after 28 days. The odds of demonstrating correct use with ELLIPTA were 6.88 times that of DISKUS plus HandiHaler (p 99% of participants made 0 critical errors (errors leading to no or significantly reduced medication inhaled) with ELLIPTA versus 89% with DISKUS plus HandiHaler after 28 days. ELLIPTA was the patient-preferred option versus DISKUS plus HandiHaler or no preference (p less then 0.001). Conclusions Delivery of COPD maintenance therapy via ELLIPTA demonstrates higher correct use rates and lower critical error rates compared with DISKUS plus HandiHaler. JCOPDF © 2020.Introduction Low-income chronic obstructive pulmonary disease (COPD) individuals are known to have higher rates of COPD-related hospitalizations and readmissions. Levels of psychological stress are also higher in low-income populations and may be associated with acute care use. We sought to (1) determine the association between stress and acute care use in COPD, (2) evaluate the social determinants of health (SDH) in low and high stress individuals, and (3) determine the association between low income and high stress with acute care use. Materials and Methods Using results from a survey-based study of individuals with COPD at the University of Alabama (UAB), we used multivariable regression modeling to evaluate the association of high stress with acute care use (COPD-related emergency department [ED] visits or hospitalizations). We then compared SDH between low and high stress groups and evaluated the association of low income + high stress with acute care use in a secondary model. Results We included 126 individuals in our study. The high stress group was more likely to be less then 65 years old and female. No differences in race, smoking, years of smoking, body mass index, dyspnea, or lung function (forced expiratory volume in 1 second [FEV1]%) by stress group were observed. The high stress group had a 2.5-fold increased adjusted odds of acute care use (adjusted odds ratio [AOR]95% confidence interval [CI], 2.51, 1.06-5.98) compared to the low stress group, while the low-income + high stress group had a 4-fold increased adjusted odds of acute care use (AOR, 95% CI, 4.38, 1.25-15-45) compared to high-income + low-stress group. Conclusions Acute care use and stress are associated in COPD. These associations are more pronounced in the low-income + high stress population who disproportionately contribute to health care utilization and frequently lack the resources needed to cope with stress. JCOPDF © 2020.

Autoři článku: Truegotfredsen3014 (Meier Silverman)